Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Transparency Notifications from Shareholders | ||||||||||||||||||||||
By: GlobeNewswire - 11 Apr 2024 | Back to overview list |
|||||||||||||||||||||
PRESS RELEASE 11 April 2024, 06:00 pm CEST Ghent, Belgium – 11 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.
_____________ (1) LSP Management Group B.V., a parent undertaking or a controlling person of LSP Health Economics Fund Management B.V. (“LSP”) informed the Company, by means of a notification dated 8 April 2024, that since 28 February 2022, LSP is no longer controlled by LSP Management Group B.V. The notification specifies furthermore that LSP Management Group B.V. was the holding company of the LSP management organization that was acquired in 2022 by the Swedish listed private equity company EQT AB. As part of that transaction, LSP Management Group B.V. has transferred the shares of LSP, among other, to EQT AB. Since then, EQT AB has held (through a pair of intermediate holding companies) all shares in LSP. This company is the sole director of LSP Sequana Holding B.V., which is a shareholder of the issuer Sequana Medical. As such, LSP exercises the voting rights of the shares of Sequana Medical. This notice is made to make it clear that LSP is no longer controlled by LSP Management Group B.V. Finally, the name of the last company has now been changed to MRMJ Holding B.V. This announcement is made in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions. To access copies of the aforementioned transparency notifications, reference is made to Sequana Medical's website (https://www.sequanamedical.com/investors/shareholder-information/). Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company. For more information, please contact: Sequana Medical Ian Crosbie, CEO About Sequana Medical Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, untolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic-resistant" patient population. alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company's Premarket Approval (PMA) application for the alfapump was submitted to the US FDA in December 2023 and accepted for substantive review in January 2024, having reported positive primary and secondary endpoint data from the North American pivotal POSEIDON study in recurrent or refractory ascites due to liver cirrhosis. Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart failure support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements. The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is planned after alfapump US PMA approval. Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com. Important Regulatory Disclaimers The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada. Note: alfapump® and DSR® are registered trademarks. Forward-looking statements This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Attachments
|
||||||||||||||||||||||
|
||||||||||||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |